DDInter1313 DDInter927
A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Norfloxacin {u} (Compound) resembles {v} (Compound) Nalidixic acid
Norfloxacin {u} (Compound) resembles {v} (Compound) Gemifloxacin
Norfloxacin {u} (Compound) binds {v} (Gene) CYP1A1
Norfloxacin {u} (Compound) upregulates {v} (Gene) GHR
Norfloxacin {u} (Compound) is included by {v} (Pharmacologic Class) Quinolones
Norfloxacin {u} (Compound) downregulates {v} (Gene) PRR7
Norfloxacin {u} (Compound) causes {v} (Side Effect) Paraesthesia
Norfloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Melphalan
Norfloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ifosfamide
Norfloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Degarelix
Norfloxacin (Compound) resembles Nalidixic acid (Compound)
Norfloxacin (Compound) resembles Gemifloxacin (Compound)
Norfloxacin (Compound) binds CYP1A1 (Gene)
Norfloxacin (Compound) upregulates GHR (Gene)
Norfloxacin (Compound) is included by Quinolones (Pharmacologic Class)
Norfloxacin (Compound) downregulates PRR7 (Gene)
Norfloxacin (Compound) causes Paraesthesia (Side Effect)
Norfloxacin may cause a minor interaction that can limit clinical effects when taken with Melphalan
Norfloxacin may cause a minor interaction that can limit clinical effects when taken with Ifosfamide
Norfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Degarelix